

Orthocell Announces Growth Factor 'Cell factory' Pipeline Publication

- Peer reviewed paper published in Journal of Bone and Joint Research
- Results further validate Orthocell's off-the-shelf regenerative solution to enhance bone growth and harvesting of tissue specific growth factors to aid in tissue healing and repair
- Cell factory-derived bioactive molecules (Growth Factors) enhance the repair of bone defects in rats
- Orthocell collaborated with Institutes in, Sweden, Australia and India to publish the successful findings

Perth, Australia; 31st October 2016: Regenerative medicine company Orthocell Limited is pleased to announce the publication of data from a successful collaboration with institutes in Sweden, India and Australia. The paper further supports Orthocell's 'Cell Factory' technology for tissue specific Growth Factors to assist in the regeneration of damaged bone tendon and cartilage tissue.

The papers objective was to investigate the osteoinductive potential of a ceramic biomaterial and growth factors secreted from local bone cells, to induce bone formation within the muscle. The outcomes demonstrated that Growth Factors derived from cultivated cells, concentrated and used in combination with scaffolds can induce effective bone repair.

Orthocell CEO Paul Anderson said, "this is an exciting further validation of our growth factor 'cell factory' pipeline technology, for a clinically and cost effective biological augment to bone cartilage and tendon repair."

"With this validation, Orthocell now has confidence to drive this exciting pipeline opportunity towards first human clinical trials."

This has been a successful international collaboration for Orthocell with the Department of Orthopaedics Clinical Sciences, Lund University, Sweden, The Centre for Orthopaedic Research, University of Western Australia, Australia and the Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India.

The Growth Factors product is planned to be an off-the-shelf product that is utilized by doctors to augment the regeneration of cartilage and bone as a whole new product line.

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au





For more information, please contact:

General enquiries

Paul Anderson

Orthocell Limited, Managing Director

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Investor and Media enquiries

Ben Walsh

WE Buchan

P: + 61 411 520 012

E: bwalsh@buchanwe.com.au

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au

